ORLANDO, Fla. — Editor’s note: This story is available as a result of a content partnership between WFTV and the Orlando Business Journal.
Employees would rather have coverage for a new class of weight-loss drugs than unlimited paid time off or child care assistance, according to results of a new survey commissioned by a health-care provider.
▶ WATCH CHANNEL 9 EYEWITNESS NEWS
The survey of 1,300 Americans by diabetes-care firm 9amHealth found that when ranking their desired job benefits in order of importance, coverage for weight-loss drugs such as Ozempic and Wegovy ranked behind only employee-sponsored health care, flexible working hours, company equity and matching 401(k) contributions. It came in ahead of unlimited PTO, work-from-home or hybrid work, and child care assistance.
The class of drugs designed to treat diabetes known as Semaglutide (within the GLP-1 classification) — a class that includes Ozempic, Wegovy and Mounjaro — has shown the potential for weight loss and has since been approved by the U.S. Food and Drug Administration, sparking a rush for the medication that has so far outstripped supply. That demand for the drug class, however, has sent its value soaring, with the list price for the medication reaching more than $900 for a month’s supply.
Click here to read the full story on the Orlando Business Journal’s website.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
©2024 Cox Media Group
